-
公开(公告)号：US20220274982A1
公开(公告)日：2022-09-01
申请号：US17630840
申请日：2020-07-28
发明人： Yuta TANAKA , Yuta TANAKA , Fumiaki KIKUCHI , Takeshi YAMAMOTO , Minoru NAKAMURA , Kazuaki TAKAMI , Masataka MURAKAMI , Masaki DAINI , Yasufumi WADA , Keiko KAKEGAWA , Takahito KASAHARA , Tomohiro OHASHI , Junsi WANG , Zenichi IKEDA , Florian PUENNER , Masaki SETO , Satoshi MIKAMI , Minoru SASAKI
IPC分类号： C07D471/04
摘要： The present invention provides a compound having a glucosylceramide synthase inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of lysosomal storage diseases (e.g., Gaucher's disease, Fabry's disease, GM1-gangliosidosis, GM2 activator deficiency, Tay-Sachs disease, Sandhoffs disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.-
公开(公告)号：US20180303841A1
公开(公告)日：2018-10-25
申请号：US15769295
申请日：2016-10-19
发明人： Takahiro SUGIMOTO , Shinkichi SUZUKI , Hiroki SAKAMOTO , Masami YAMADA , Minoru NAKAMURA , Makoto KAMATA , Kenichiro SHIMOKAWA , Masaki OGINO , Eiji KIMURA , Masataka MURAKAMI , Takuto KOJIMA , Jinichi YONEMORI
CPC分类号： A61K31/53 , A61K31/517 , A61P25/04 , A61P25/16 , A61P25/18 , A61P25/28 , C07D239/88 , C07D401/06 , C07D401/14 , C07D403/06 , C07D403/10 , C07D405/14
摘要： The present invention provides a compound which has a cholinergic muscarinic M1 receptor positive allosteric modulator activity and may be useful as a medicament such as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, Lewy body dementia and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. In the formula (I), each symbol is as described in the attached specification.
-
公开(公告)号：US20240309016A1
公开(公告)日：2024-09-19
申请号：US18606857
申请日：2024-03-15
发明人： Mitsunori KONO , Yusuke SASAKI , Yuya OGURO , Zenichi IKEDA , Osamu KUBO , Masaki SETO , Toru YAMASHITA , Makoto KAMATA , Kenjiro SATO , Matthew Thomas REYNOLDS , Kazuaki TAKAMI , Asato KINA , Takafumi YUKAWA , Minoru NAKAMURA , Taku KAMEI , Hiroyuki KAKEI , Fumie YAMAGUCHI , Tomohiro OHASHI , Keiko KAKEGAWA , Takuto KOJIMA , Florian PÜNNER , Masataka MURAKAMI , Takahiko TANIGUCHI , Tatsuki KOIKE , Yuichi KAJITA , Yuhei MIYANOHANA , Kohei TAKEUCHI , Yoshiteru ITO , Norihito TOKUNAGA , Yasushi HATTORI , Eiji KIMURA , Martin Alexander PAWLICZEK , Marilena PIRA , Shuhei IKEDA , Noriyuki TEZUKA , Yoshikazu WATANABE , Kevin CURRAN , Nicolle DOERING , Maria HOPKINS , Ben JOHNSON , Andre KIRYANOV , Jon LAM , Sean MURPHY , Natasha O'ROURKE , Holly REICHARD , Paul TANIS , Yunlong ZHANG
IPC分类号： C07D498/14 , A61K31/407 , A61K31/437 , A61P25/26 , C07D498/04
CPC分类号： C07D498/14 , A61K31/407 , A61K31/437 , A61P25/26 , C07D498/04
摘要： The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):
wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.-
公开(公告)号：US20200255439A1
公开(公告)日：2020-08-13
申请号：US16651840
申请日：2018-09-27
发明人： Makoto KAMATA , Hideyuki SUGIYAMA , Minoru NAKAMURA , Masataka MURAKAMI , Shuhei IKEDA , Tomohiro OKAWA , Hidekazu TOKUHARA
IPC分类号： C07D487/10 , A61P25/28 , A61K9/48 , A61K9/20
摘要： The present invention provides a compound having an MAGL inhibitory action, and expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
-
公开(公告)号：US20160376244A1
公开(公告)日：2016-12-29
申请号：US15190642
申请日：2016-06-23
发明人： Takahiro SUGIMOTO , Shinkichi SUZUKI , Hiroki SAKAMOTO , Masami YAMADA , Minoru NAKAMURA , Makoto KAMATA , Kenichiro SHIMOKAWA , Masaki OGINO , Eiji KIMURA , Masataka MURAKAMI , Jinichi YONEMORI , Takuto KOJIMA
IPC分类号： C07D265/22 , C07D413/06 , C07D491/107 , C07D413/04 , C07F7/02 , C07D471/04 , C07D413/14 , C07D413/10
CPC分类号： C07D413/14 , A61P25/28 , C07B2200/07 , C07D265/22 , C07D413/04 , C07D413/06 , C07D413/10 , C07D417/06 , C07D417/10 , C07D471/04 , C07D491/107 , C07F7/02 , C07F7/0814
摘要： The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
摘要翻译： 其中每个符号如所附的说明中所定义。
-
公开(公告)号：US20240217957A1
公开(公告)日：2024-07-04
申请号：US18522917
申请日：2023-11-29
发明人： Asato KINA , Zenichi IKEDA , Mitsunori KONO , Yuya OGURO , Osamu KUBO , Toru YAMASHITA , Kazuaki TAKAMI , Takafumi YUKAWA , Masaki SETO , Makoto KAMATA , Kenjiro SATO , Masataka MURAKAMI , Yusuke SASAKI , Matthew Thomas REYNOLDS , Minoru NAKAMURA , Taku KAMEI , Hiroyuki KAKEI , Fumie YAMAGUCHI , Tomohiro OHASHI , Takuto KOJIMA , Keiko KAKEGAWA , Florian PÜNNER , Shinji NAKAMURA , Nao MORISHITA , Tadashi HIDAKA , Sachie TAKASHIMA , Takahiko TANIGUCHI
IPC分类号： C07D413/04 , A61P25/00 , C07D413/14
CPC分类号： C07D413/04 , A61P25/00 , C07D413/14
摘要： The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. Provided is a compound of formula (I):
wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.-
公开(公告)号：US20230150934A1
公开(公告)日：2023-05-18
申请号：US18087233
申请日：2022-12-22
发明人： Shuhei IKEDA , Makoto KAMATA , Yuya OGURO , Jumpei AIDA , Taisuke TAWARAISHI , Takeshi WAKABAYASHI , Norio OYABU , Atsuko OCHIDA , Kouichi IWANAGA , Satoshi YAMAMOTO , Masataka MURAKAMI , Minoru NAKAMURA , Fumie YAMAGUCHI , Takafumi YUKAWA
IPC分类号： C07D207/263 , A61P25/18 , C07D401/06
CPC分类号： C07D207/263 , A61P25/18 , C07D401/06
摘要： A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.
-
公开(公告)号：US20230002318A1
公开(公告)日：2023-01-05
申请号：US17755907
申请日：2020-11-12
发明人： Shuhei IKEDA , Makoto KAMATA , Yuya OGURO , Jumpei AIDA , Taisuke TAWARAISHI , Takeshi WAKABAYASHI , Norio OYABU , Atsuko OCHIDA , Kouichi IWANAGA , Satoshi YAMAMOTO , Masataka MURAKAMI , Minoru NAKAMURA , Fumie YAMAGUCHI , Takafumi YUKAWA
IPC分类号： C07D207/263 , C07D401/06 , A61P25/18
摘要： A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.
-
公开(公告)号：US20170283406A1
公开(公告)日：2017-10-05
申请号：US15474192
申请日：2017-03-30
发明人： Shuhei Ikeda , Hideyuki SUGIYAMA , Jumpei AIDA , Hidekazu TOKUHARA , Tomohiro OKAWA , Yuya OGURO , Minoru NAKAMURA , Masataka MURAKAMI
IPC分类号： C07D413/14 , C07D413/08 , C07D405/14 , C07D401/08
CPC分类号： C07D413/14 , C07D401/06 , C07D401/08 , C07D405/14 , C07D413/06 , C07D413/08
摘要： The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
-
公开(公告)号：US20230134307A1
公开(公告)日：2023-05-04
申请号：US18087302
申请日：2022-12-22
发明人： Shuhei IKEDA , Makoto KAMATA , Yuya OGURO , Jumpei AIDA , Taisuke TAWARAISHI , Takeshi WAKABAYASHI , Norio OYABU , Atsuko OCHIDA , Kouichi IWANAGA , Satoshi YAMAMOTO , Masataka MURAKAMI , Minoru NAKAMURA , Fumie YAMAGUCHI , Takafumi YUKAWA
IPC分类号： C07D207/263 , A61P25/18 , C07D401/06
摘要： A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.031 秒)
